Dr. Christopher G. Wang, M.D
Hematology & Oncology (Hematology & Oncology Physician)
2022 Brookwood Medical Ctr Dr, Ambulatory Care Center, Ste 628
Birmingham, AL 35209
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 606
Licensed in Alabama since 2012, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license 31731 (first issued 2012; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Grandview Medical Center Birmingham, AL
Medical groups
- Birmingham Hematology Oncology Assoc LLC (32 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 606
- Services billed
- 129,434
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 49,500 | 42 |
| Injection, oxaliplatin, 0.5 mg | 11,800 | 11 |
| Injection, immune globulin (bivigam), 500 mg | 6,340 | 17 |
| Injection, denosumab, 1 mg | 4,860 | 31 |
| Flow cytometry technique for dna or cell analysis, each additional marker | 4,279 | 162 |
| Injection, ferric derisomaltose, 10 mg | 3,700 | 34 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,155 | 48 |
| Insertion of needle into vein for collection of blood sample | 1,027 | 391 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 943 | 360 |
| Injection, granisetron hydrochloride, 100 mcg | 450 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Birmingham, AL | 205 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Birmingham, AL | 118 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Birmingham, AL | 114 |
| Revlimid (lenalidomide) | 90 |
| Letrozole Other prescribers in Birmingham, AL | 90 |
| Oxycodone Hcl Other prescribers in Birmingham, AL | 78 |
| Gabapentin Other prescribers in Birmingham, AL | 71 |
| Dexamethasone Other prescribers in Birmingham, AL | 66 |
| Clonazepam Other prescribers in Birmingham, AL | 65 |
| Hydroxyurea Other prescribers in Birmingham, AL | 61 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 43 companies reported 162 payments worth $3,313 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $402 |
|---|---|
| Merck Sharp & Dohme LLC | $233 |
| Janssen Biotech, Inc. | $230 |
| AbbVie Inc. | $208 |
| AstraZeneca Pharmaceuticals LP | $183 |
| Celgene Corporation | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | $147 |
| E.r. Squibb & Sons, L.l.c. | $142 |
| Food and Beverage | $3,313 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $24,147 in research payments for these studies, mostly to the institutions running them.
- A randomized phase 3 openlabel study to evaluate SGNB6A compared with docetaxel in adult subjects with previously treated nonsmall cell lung cancer
Pfizer Inc. - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958 - A randomized phase 3 openlabel study to evaluate PF08046054SGNPDL1V versus docetaxel in adult participants with previouslytreated programmed cell death ligand 1 PDL1 positive nonsmallcell lung cancer nsclc
Pfizer Inc. - Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT01838512
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.